ArticleCell reports methods2026
Uncertainty-aware graph structure optimization with ensemble learning for enhanced cancer gene identification.
Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The heterogeneity and noise of biological networks reduce prediction accuracy. We propose NexusGene, a computational framework that integrates uncertainty-aware graph structure learning (UnGSL) with clustering-enhanced ensemble learning to improve cancer gene identification in complex biological networks. UnGSL refines the graph structure by quantifying uncertainty in node features and adjusting edge weights to mitigate the influence of noisy or unreliable data. Additionally, a clustering-enhanced ensemble learning strategy reduces prediction bias and false negatives by optimizing base learners based on gene distribution patterns and combining predictions from multiple models. NexusGene was benchmarked against six current methods across seven pan-cancer and 31 cancer-specific networks, consistently achieving the best overall performance, with particularly strong gains in heterogeneous settings. These results establish NexusGene as a robust and interpretable framework for cancer gene discovery across diverse cancer contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.